Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 23, 2007. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares in accordance with shareholder authority granted at the Annual General Meeting on May 17, 2006.
Key Financial Metrics
The filing does not provide comprehensive financial statements such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 750,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,393.95 pence per share.
- Treasury Holdings: Following this transaction, the Company holds 244,482,678 shares in Treasury.
- Shares in Issue: 5,751,968,657 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of outstanding shares due to the repurchase of 750,000 shares. Consequently, the total number of shares held in Treasury increased to 244,482,678. The filing does not provide comparative data against prior periods for operational or financial performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Transparency Directive's transitional provision 6.
Investor Verification Checklist
- Verify the total number of shares in issue (5,751,968,657) for calculating voting rights and disclosure thresholds under Financial Services Authority rules.
- Confirm the updated Treasury share count (244,482,678) for accurate share capital analysis.
- Note that this filing is a transactional report and does not contain quarterly or annual financial performance data.